$HIND News

Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025

Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5

Vyome Appoints Jerry Leonard As CFO On August 27, 2026

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X

Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting

Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR

Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Announces Publication Of Preclinical Data For Uveitis Treatment VT-1908

Vyome Announces Publication Of Preclinical Data For Uveitis Treatment VT-1908

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results